Please upgrade your browser.
High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Typ
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R).
If you are a kidney cancer patient, 18 years of age or older, and you live in the NYC or Philadelphia area, we invite you to participate in this research. Interviews will take approximately 45 minutes and can be conducted at a location near your home between Dec 15 - 19, 2014.
The drug designed to keep him alive may have hastened his death
Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel
nce the approval of sorafenib in December 2005, several targeted therapeutic agents have been approved by the FDA for the treatment of advanced renal cell carcinoma (RCC).
Statin use at the time of surgery is associated with improved overall survival (OS) and disease-specific survival (DSS) in patients with renal cell carcinoma (RCC) of any stage, US researchers report.
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs.
The KCA has earned its seventh consecutive 4-star rating from Charity Navigator
Kidney Cancer Association Patient and Survivor Conference to be Held in North Carolina December 13, 2014
The University of North Carolina will be hosting its second conference for kidney cancer patients and their families on Saturday, December 13, 2014.
|Powered by NeonCRM|